If you were waiting for a pullback on Dendreon Corp. (NASDAQ:DNDN) shares, here's your chance. In just five trading sessions Dendreon shares have dropped from $34.50 to $26, and today they have managed to get back to $27.80. Buy on the dip or could more pain be coming?
Dendreon Corporation (NASDAQ:DNDN) could have an instant $1 billion in sales if the FDA votes to approve the company's cancer treatment drug Provenge on May 1st. Dendreon shares have increased 700% in the last 12 months, but come May if the company gets the green light, its going to be a gold rush.